Mar 31, 2022 / 03:00PM GMT
Seamus Christopher Fernandez - Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals
Okay. Well, good morning, everybody, and thank you very much for joining us at Guggenheim's Genomic Medicines and Rare Disease Day. I'm Seamus Fernandez, one of Guggenheim's [part] pharmaceutical analyst. Really pleased to be joined here today by Saurabh Saha, Chief Executive Officer of Centessa Pharmaceuticals.
Saurabh, I know that there's been a lot going on at the company. So we wanted to make sure that you had an opportunity to really tell the story in complete fashion. So for everybody who's listening, Saurabh is going to go through the Centessa -- an abbreviated presentation. that will last about 25 minutes, and then we'll jump right into Q&A. Saurabh, thanks so much for joining us. Really excited to hear about all the progress at Centessa.
Saurabh Saha - Centessa Pharmaceuticals plc - CEO & Director
Great. Well, thank you for the introduction, Seamus, and I appreciate the invitation to speak here. So it's really great to
Centessa Pharmaceuticals PLC at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Mar 31, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers